Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF)

Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF)

Abstract Background Tuberculosis (TB) is a significant public health problem that causes substantial morbidity and mortality. Current first-line anti-TB chemotherapy, although very effective, has limitations including long-treatment duration with a possibility of non-adherence, drug interactions, an...

Full description

Bibliographic Details
Main Authors: Ruth Nabisere, Joseph Musaazi, Paolo Denti, Florence Aber, Mohammed Lamorde, Kelly E. Dooley, Rob Aarnoutse, Derek J. Sloan, Christine Sekaggya-Wiltshire
Format: Article
Language:English
Published: BMC 2020-02-01
Series:Trials
Subjects:
Rifamycins
Antiretrovirals
HIV
Pharmacokinetics
Tuberculosis
Online Access:https://doi.org/10.1186/s13063-020-4132-7

Internet

https://doi.org/10.1186/s13063-020-4132-7

Similar Items